Serum S100A8/A9 May Act as Biomarker of Atherosclerosis Severity in Psoriasis

Myocardial infarction remains the leading cause of death worldwide despite an improvement in outcomes over the last several decades (Reed et. al., 2017). Although primary prevention of cardiovascular disease through pharmacological measures has been a key part of this progress, many patients have comorbidities that independently increase their cardiovascular risk. In their linked article, “Association of S100A8/A9 with lipid-rich necrotic core (LRNC) and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study” (Berg et al., 2022), the authors present data to further elucidate the complex relationship between psoriasis and cardiovascular health.